Margaret Macro

Centre Hospitalier Universitaire de Caen Normandie — France

Medicine · Health Sciences

47h-index13.3kcitations257works8.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(188), Protein Degradation and Inhibitors(78), Cancer Treatment and Pharmacology(51), Peptidase Inhibition and Analysis(49), Chronic Lymphocytic Leukemia Research(30)

Publications257 total

Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)
JMIR Formative Research·2025Open Access
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Blood Cancer Journal·2025· 1 citedOpen Access
Daratumumab(Dara) Lenalidomide(R) Maintenance Following Dara-Carfilzomib(K)R Dexamethasone with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Update of the Phase 2 Study IFM 2018-04
Clinical Lymphoma Myeloma & Leukemia·2025
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022–05)
Clinical Lymphoma Myeloma & Leukemia·2025
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study
Haematologica·2025Open Access
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort
Clinical Lymphoma Myeloma & Leukemia·2025· 1 citedOpen Access
A Patient-Centered education through Massive Open Online Course (MOOC) for Multiple Myeloma: A Descriptive Study of Knowledge Gains by AF3M and IFM (Preprint)
2025Open Access
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study
Clinical Lymphoma Myeloma & Leukemia·2025
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Journal of Thrombosis and Haemostasis·2025· 1 cited
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
Blood·2025· 17 citedOpen Access
Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐<scp>CD38</scp> Antibodies: The <scp>EMMY</scp> Cohort From 2017 to 2020
Cancer Medicine·2025· 1 citedOpen Access
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Leukemia·2025· 26 citedOpen Access
Mise en place de consultations pharmaceutiques initiales et de suivi en onco-hématologie : bilan à deux ans et perspectives
Annales Pharmaceutiques Françaises·2025
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial
Blood·2025· 21 citedOpen Access
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
Leukemia·2025· 5 cited
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
British Journal of Haematology·2025· 4 citedOpen Access
[Multiple myeloma of the bones].
PubMed·2025
Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG
Blood·2024· 3 cited
High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
Blood·2024· 2 cited
OA-47 Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update
Clinical Lymphoma Myeloma & Leukemia·2024
page 1 of 13Next →

Frequent Co-authors

Xavier Leleu(28), Thierry Façon(28), Philippe Moreau(28), Hervé Avet‐Loiseau(26), Michel Attal(21), Karim Belhadj(19), Aurore Perrot(19), Denis Caillot(18), Murielle Roussel(17), Mourad Tiab(16), Cyrille Hulin(15), Bertrand Arnulf(14), Laurent Garderet(14), Jill Corre(14), Bruno Royer(14), Gérald Marit(13), Cyrille Hulin(13), Sabine Bréchignac(13), Mohamad Mohty(13), Lionel Karlin(12)